

Using the IMgateway drug interactions in the new eMIMSCloud

IMgateway is the herb-drug, supplement-drug and food-drug interactions database available as an additional module in the new eMIMS. This ever evolving, evidence-based drug interactions database, published by Unity Health, now contains over 650 interactions and brings an added dimension to eMIMS. Through the IMgateway interactions database, users will now also have access to another first: drug interactions with Traditional Chinese Medicines (TCM) and Japanese Kampo Medicines.

Adding medicines to the interaction checker is simple and can be done from different points of your workflow.

IMgateway interactions can be accessed from the Interactions Checker in the NavBar and by clicking

the IMgateway tab. If you see an IMGateway Interactions button on the search results page, or the IMGATEWAY symbol next to a generic ingredient in a PI, this indicates IMgateway information is available for this drug/ herb and clicking on the link will open a new browser tab with the relevant information displayed.

1) From the Medicines Information module:

Atorva	statin	Search Browse Search Tips
Search res	ults for Atorvastatin	
Need to narro	w down ? Refine your searc	Didn't find what you want? Try Advanced Search
Results 1-2	0 of 30	
APO-Atorvast	atin (Tablets) [Apotex] 🕖	
APO-Atorvast Atorvastatin	atin (Tablets) [Apotex] 🗘	
APO-Atorvasta Atorvastatin Use:	atin (Tablets) [Apotex] 🕖 HMG-CoA reductase inhib	itor. Adjunct to diet in treatment of hypercholesterolaemia; nonfatal MI,
APO-Atorvasta Atorvastatin Use:	atin (Tablets) [Apotex] 🖸 HMG-CoA reductase inhit stroke risk reduction in h	itor. Adjunct to diet in treatment of hypercholesterolaemia; nonfatal MI, ypertensive patients with multiple CHD risks. See Section 2(f) headnote
APO-Atorvast Atorvastatin Use: Dose:	atin (Tablets) [Apotex] HMG-CoA reductase inhit stroke risk reduction in h Individualise dose; 10-80	itor. Adjunct to diet in treatment of hypercholesterolaemia; nonfatal MI, ypertensive patients with multiple CHD risks. See Section 2(f) headnote I mg once daily; may adjust dose after 4 wks according to response.
APO-Atorvast Atorvastatin Use: Dose:	atin (Tablets) [Apotex] HMG-CoA reductase inhit stroke risk reduction in h Individualise dose; 10-80 Primary hypercholesterol	itor. Adjunct to diet in treatment of hypercholesterolaemia; nonfatal MI, ypertensive patients with multiple CHD risks. See Section 2(f) headnote mg once daily; may adjust dose after 4 wks according to response. aemia, mixed dyslipidaemia: 10 mg/day. Homozygous familial
APO-Atorvast Atorvastatin Use: Dose:	atin (Tablets) [Apotex] HMG-CoA reductase inhit stroke risk reduction in h Individualise dose; 10-8(Primary hypercholesterol hypercholesterolaemia. A	itor. Adjunct to diet in treatment of hypercholesterolaemia; nonfatal MI, ypertensive patients with multiple CHD risks. See Section 2(f) headnote mg once daily; may adjust dose after 4 wks according to response. aemia, mixed dyslipidaemia: 10 mg/day. Homozygous familial dults: 80 mg/day. Concomitant cyclosporin, telaprevir, tipranavir +
APO-Atorvast Atorvastatin Use: Dose:	atin (Tablets) [Apotex] HMG-CoA reductase inhit stroke risk reduction in h Individualise dose; 10-8(Primary hypercholesterol hypercholesterolaemia. A ritonavir: max atorvastat	itor. Adjunct to diet in treatment of hypercholesterolaemia; nonfatal MI, ypertensive patients with multiple CHD risks. See Section 2(f) headnote I mg once daily; may adjust dose after 4 wks according to response. aemia, mixed dyslipidaemia: 10 mg/day. Homozygous familial dults: 80 mg/day. Concomitant cyclosporin, telaprevir, tipranavir + in 10 mg. Fusidic acid (see Contra): discontinue atorvastatin, may
APO-Atorvast Atorvastatin Use: Dose:	atin (Tablets) [Apotex] HMG-CoA reductase inhit stroke risk reduction in h Individualise dose; 10-80 Primary hypercholesterol hypercholesterolaemia. A ritonavir: max atorvastat reintroduce 7 days after	itor. Adjunct to diet in treatment of hypercholesterolaemia; nonfatal MI, ypertensive patients with multiple CHD risks. See Section 2(f) headnote mg once daily; may adjust dose after 4 wks according to response. aemia, mixed dyslipidaemia: 10 mg/day. Homozygous familial dults: 80 mg/day. Concomitant cyclosporin, telaprevir, tipranavir + in 10 mg. Fusidic acid (see Contra): discontinue atorvastatin, may ast fusidic acid dose
APO-Atorvast Atorvastatin Use: Dose: MIMS Class:	atin (Tablets) [Apotex] HMG-CoA reductase inhit stroke risk reduction in h Individualise dose; 10-80 Primary hypercholesterol hypercholesterolaemia. A ritonavir: max atorvastat reintroduce 7 days after Hypolipidaemic agents	itor. Adjunct to diet in treatment of hypercholesterolaemia; nonfatal MI, ypertensive patients with multiple CHD risks. See Section 2(f) headnote mg once daily; may adjust dose after 4 wks according to response. aemia, mixed dyslipidaemia: 10 mg/day. Homozygous familial dults: 80 mg/day. Concomitant cyclosporin, telaprevir, tipranavir + in 10 mg. Fusidic acid (see Contra): discontinue atorvastatin, may ast fusidic acid dose
APO-Atorvast Atorvastatin Use: Dose: MIMS Class: Drug Image:	Atin (Tablets) [Apotex] HMG-CoA reductase inhib stroke risk reduction in h Individualise dose; 10-80 Primary hypercholesterol hypercholesterolaemia. A ritonavir: max atorvastat reintroduce 7 days after Hypolipidaemic agents APO (APO) (APO) (APO)	itor. Adjunct to diet in treatment of hypercholesterolaemia; nonfatal MI, ypertensive patients with multiple CHD risks. See Section 2(f) headnote mg once daily; may adjust dose after 4 wks according to response. aemia, mixed dyslipidaemia: 10 mg/day. Homozygous familial dults: 80 mg/day. Concomitant cyclosporin, telaprevir, tipranavir + in 10 mg. Fusidic acid (see Contra): discontinue atorvastatin, may ast fusidic acid dose
APO-Atorvast Atorvastatin Use: Dose: MIMS Class: Drug Image:	Atin (Tablets) [Apotex] HMG-CoA reductase inhib stroke risk reduction in h Individualise dose; 10-80 Primary hypercholesterol hypercholesterolaemia. A ritonavir: max atorvastat reintroduce 7 days after Hypolipidaemic agents APO APO APO 10 20 80	itor. Adjunct to diet in treatment of hypercholesterolaemia; nonfatal MI, ypertensive patients with multiple CHD risks. See Section 2(f) headnote mg once daily; may adjust dose after 4 wks according to response. aemia, mixed dyslipidaemia: 10 mg/day. Homozygous familial dults: 80 mg/day. Concomitant cyclosporin, telaprevir, tipranavir + in 10 mg. Fusidic acid (see Contra): discontinue atorvastatin, may ast fusidic acid dose
APO-Atorvast Atorvastatin Use: Dose: MIMS Class: Drug Image: PBS:	Atin (Tablets) [Apotex] HMG-CoA reductase inhib stroke risk reduction in h Individualise dose; 10-80 Primary hypercholesterol hypercholesterolaemia. A ritonavir: max atorvastat reintroduce 7 days after Hypolipidaemic agents APO APO APO 10 20 80 Restricted - PBS/RPBS, Re	itor. Adjunct to diet in treatment of hypercholesterolaemia; nonfatal MI, ypertensive patients with multiple CHD risks. See Section 2(f) headnote mg once daily; may adjust dose after 4 wks according to response. aemia, mixed dyslipidaemia: 10 mg/day. Homozygous familial dults: 80 mg/day. Concomitant cyclosporin, telaprevir, tipranavir + in 10 mg. Fusidic acid (see Contra): discontinue atorvastatin, may ast fusidic acid dose

Once you have performed a search you will get a list of medicines that match that search. If one or more generic ingredients have an interaction with in the IMgateway module you will find a link which will take directly to the module and the information you want to view

Copyright MIMS Australia Pty Ltd Locked Bag 3000, St Leonards NSW 1590 Phone: (02) 9902 7700, Facsimile: (02) 9902 7701 <u>www.mims.com.au</u> ACN 050 695 157, ABN 68 050 695 157



2) From the PI

If you choose the Full PI of a medicine with multiple generic ingredients from your search list, all the ingredients that have a drug interaction will be flagged with this symbol

Caduet			This too will take you straight to the
Amlodipine , Atorva	astatin IMGATEWAY	$\mathbf{\hat{>}}$	IMgateway module and the details you
Abbreviated PI	Full PI	CMI	are looking for

3) From the Interactions Checker

You can access the Imgateway drug interactions directly from the interaction checker. Here you have options;-

- M Choose a herb only
- M Choose drug only
- M Choose a therapeutic class only
- M Choose combinations of herbs and a drug
- M Choose a herb and therapeutic class

The IMgateway data base has a broad selection of herbs, supplements and food. The module is continually evolving and in September we added some Traditional Chinese Medicines (TCMs) and some Japanese Kampo medicines.

A first for Australia and one we are very proud of being able to deliver to our eMIMS users

nteractions C	hecker		
MIMS IMgateway	/		
		DRUG	
HERB / SUPPLEMENT / FOO	D		
ALL	• •	OR	
		DRUG CLASS	
		Search Tips	
		clear	search
			Bearen



HERB / SUPPL	EMENT / FOOD				
Calcium	/	- +		OR	
			DRUG	CLASS	
			Search Tip	IS	
				clear s	earch
Please refer to Disclai	mer				
Interaction Res	ults Interaction	Details			
Herb	Drug	Drug Class		Recommendation	
Calcium	Ceftriaxone	Cephalosporins		Avoid combination	more »
Calcium	Ciprofloxacin	Quinolones		Avoid combination	more »
Calcium	Demeclocycline	Tetracyclines		Avoid combination	more »
Calcium	Doxycycline	Tetracyclines		Avoid combination	more »
Calcium	Minocycline	Tetracyclines		Avoid combination	more »
Calcium	Norfloxacin	Quinolones		Avoid combination	more »
Calcium	Tetracycline	Tetracyclines		Avoid combination	more »
Calcium	Sotalol	Beta-adrenergic t agents	olocking	Caution	more »
Calcium	Thyroxine	Thyroid hormones antithyroid agent	s and s	Caution	more »
Calcium	Moxifloxacin	Quinolones		Unlikely	more

Interaction 1 of 10

Calcium + Ceftriaxone

GENERAL RECOMMENDATION

Avoid combination

ADVICE TO THE PATIENT

Several case reports have described eases of respiratory failure, kidney failure and death in neonates (aged <28 days) that have been co-administered IV ceftriaxone and IV calcium-containing products, either via the same or separate intravenous lines. The US Food and Drug Administration has contraindicated ceftriaxone and IV calcium-containing products in neonates, and strongly recommends that ceftriaxone and IV calcium-containing products should never be administered simultaneously via a Y-site in any age group. These recommendations apply to any intravenous product containing calcium (including parenteral nutrition and Ringer's solution).

EVIDENCE TYPE

REPORT

Good

Not Established

GENERAL COMMENTARY ON EVIDENCE

Ceftriaxone and calcium have been shown to form complexes and precipitate when given together intravenously at sufficient concentrations. While neonates appear to be at the greatest risk of harm due to this interaction and then have not been reported cases in adults, extreme caution is warranted. There is currently no data available on the use of ceftriaxone with oral calcium-containing products, however no cases have been reported at present. Refer to full FDA recommendations in the Reports section below.

Limited

You can also click a link through to any reports included these can be saved to your favourites, saved as PDF, emailed and/or printed. You can even make the font bigger.

Copyright MIMS Australia Pty Ltd Locked Bag 3000, St Leonards NSW 1590 Phone: (02) 9902 7700, Facsimile: (02) 9902 7701 <u>www.mims.com.au</u> ACN 050 695 157, ABN 68 050 695 157 — Choose the herb/supplement or food you wish to review

A list of interactions is displayed below the search and immediately you will see which medicines interact, to which class they belong and what the recommended course of action is.

To see more detail simply click on more

Once you click through to the details of an interaction you will find advice for the patient, the evidence type and a general commentary on the evidence.



Report Details



FDA INFORMATION FOR HEALTHCARE PROFESSIONALS: CEFTRIAXONE (21/4/2009)

http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformat Last updated 21/4/2009. Accessed 5/1/2012.

Results

This Alert highlights important revisions to the Warnings, Dosage and Administration, Contraindications, and Clinical Pharmacology sections of the full prescribing information for ceftriaxone (Rocephin and its generics). This information updates a previous Alert and addresses the interaction of ceftriaxone with calcium-containing products, based on

The Imgateway module is an additional subscription to eMIMS

To subscribe or to get more information please call our Client Services Team

On 1800 1800 629 or visit our website mims.com.au

Copyright MIMS Australia Pty Ltd Locked Bag 3000, St Leonards NSW 1590 Phone: (02) 9902 7700, Facsimile: (02) 9902 7701 <u>www.mims.com.au</u> ACN 050 695 157, ABN 68 050 695 157